Cargando…

Role of tannic acid against SARS-cov-2 cell entry by targeting the interface region between S-protein-RBD and human ACE2

Coronavirus disease 2019 (COVID-19) was caused by a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 utilizes human angiotensin converting enzyme 2 (hACE2) as the cellular receptor of its spike glycoprotein (SP) to gain entry into cells. Consequently, we focu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xi, Wang, Ziyuan, Wang, Jing, Yao, Yifan, Wang, Qian, Huang, Jiahao, Xiang, Xianping, Zhou, Yifan, Xue, Yintong, Li, Yan, Gao, Xiang, Wang, Lijun, Chu, Ming, Wang, Yuedan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393390/ https://www.ncbi.nlm.nih.gov/pubmed/36003511 http://dx.doi.org/10.3389/fphar.2022.940628

Ejemplares similares

Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
por: Gurung, Arun Bahadur, et al.
Publicado: (2021)

1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection
por: Chen, Rui Hong, et al.
Publicado: (2021)

Tuftsin: A Natural Molecule Against SARS-CoV-2 Infection
por: Huang, Jiahao, et al.
Publicado: (2022)

In silico study of intrinsic dynamics of full-length apo-ACE2 and RBD-ACE2 complex
por: Liu, Qing, et al.
Publicado: (2021)

Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
por: Lan, Jun, et al.
Publicado: (2022)

Cross-species binding spectrum of ACE2 to SARS-CoV-2 RBD
por: Liao, Xihao, et al.
Publicado: (2022)

Combined proteomic and transcriptomic analysis of the antimicrobial mechanism of tannic acid against Staphylococcus aureus
por: Wang, Jing, et al.
Publicado: (2023)

RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor
por: Sinha, Siddharth, et al.
Publicado: (2021)

Entropic contribution of ACE2 glycans to RBD binding
por: Mugnai, Mauro L., et al.
Publicado: (2023)

The Mechanism Underlying the Protective Effects of Tannic Acid Against Isoproterenol-Induced Myocardial Fibrosis in Mice
por: Ma, Donglai, et al.
Publicado: (2020)

Effect of Delta and Omicron Mutations on the RBD-SD1 Domain of the Spike Protein in SARS-CoV-2 and the Omicron Mutations on RBD-ACE2 Interface Complex
por: Ching, Wai-Yim, et al.
Publicado: (2022)

Structure-Based Virtual Screening and Identification of Potential Inhibitors of SARS-CoV-2 S-RBD and ACE2 Interaction
por: Xiong, Jiacheng, et al.
Publicado: (2021)

In silico investigations of heparin binding to SARS‐CoV‐2 variants with a focus at the RBD/ACE2 interface
por: Ali, Nemat, et al.
Publicado: (2022)

A Novel Modulator of the Renin–Angiotensin System, Benzoylaconitine, Attenuates Hypertension by Targeting ACE/ACE2 in Enhancing Vasodilation and Alleviating Vascular Inflammation
por: Zhang, Qi-Qiang, et al.
Publicado: (2022)

Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor
por: Kim, Young Soo, et al.
Publicado: (2021)

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
por: Bertoglio, Federico, et al.
Publicado: (2021)

Scanning the RBD-ACE2 molecular interactions in Omicron variant
por: Rath, Soumya Lipsa, et al.
Publicado: (2022)

Physical Activity and Inhibition of ACE Additively Modulate ACE/ACE-2 Balance in Heart Failure in Mice
por: Tyrankiewicz, Urszula, et al.
Publicado: (2021)

Th2A cells: The pathogenic players in allergic diseases
por: Huang, Ziyu, et al.
Publicado: (2022)

The Development of Pharmacophore Models for the Search of New Natural Inhibitors of SARS-CoV-2 Spike RBD–ACE2 Binding Interface
por: Semenov, Valentin A., et al.
Publicado: (2022)

Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection
por: Xu, Zhen, et al.
Publicado: (2022)

Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2
por: Lai, Yen-Chung, et al.
Publicado: (2022)

Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2
por: He, Ming-Feng, et al.
Publicado: (2022)

Characterization of Critical Determinants of ACE2–SARS CoV-2 RBD Interaction
por: Brown, Emily E. F., et al.
Publicado: (2021)

Exploring the disruption of SARS-CoV-2 RBD binding to hACE2
por: Carter, Camryn, et al.
Publicado: (2023)

Can polyoxometalates (POMs) prevent of coronavirus 2019-nCoV cell entry? Interaction of POMs with TMPRSS2 and spike receptor domain complexed with ACE2 (ACE2-RBD): Virtual screening approaches
por: Shahabadi, Nahid, et al.
Publicado: (2022)

Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions
por: Liu, Xiaofeng, et al.
Publicado: (2023)

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
por: Junker, Daniel, et al.
Publicado: (2022)

A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site
por: He, Siqi, et al.
Publicado: (2023)

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface
por: Bertoglio, Federico, et al.
Publicado: (2021)

TFDP3 as E2F Unique Partner, Has Crucial Roles in Cancer Cells and Testis
por: Huang, Jiahao, et al.
Publicado: (2021)

A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2
por: Wang, Xiaoning, et al.
Publicado: (2021)

Advanced Analysis of Biosensor Data for SARS-CoV-2 RBD and ACE2 Interactions
por: Forssén, Patrik, et al.
Publicado: (2020)

Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding
por: Yang, Li Jun, et al.
Publicado: (2021)

SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility
por: Valério, Mariana, et al.
Publicado: (2022)

TRIM28 regulates SARS-CoV-2 cell entry by targeting ACE2
por: Wang, Yinfang, et al.
Publicado: (2021)

Augmented Renal Clearance: What Have We Known and What Will We Do?
por: Luo, Yifan, et al.
Publicado: (2021)

Polypharmacology of Berberine Based on Multi-Target Binding Motifs
por: Chu, Ming, et al.
Publicado: (2018)

Saikosaponin A, a Triterpene Saponin, Suppresses Angiogenesis and Tumor Growth by Blocking VEGFR2-Mediated Signaling Pathway
por: Zhang, Pan, et al.
Publicado: (2021)

Molecular dynamics simulations and functional studies reveal that hBD-2 binds SARS-CoV-2 spike RBD and blocks viral entry into ACE2 expressing cells
por: Zhang, Liqun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eb21j45nl6j5hhimk7fekjnq6v